Flexitouch Treatment for Venous Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00847002
Recruitment Status : Terminated (Lack of Enrollment)
First Posted : February 19, 2009
Results First Posted : July 25, 2012
Last Update Posted : October 21, 2016
Information provided by (Responsible Party):
Tactile Medical ( Tactile Systems Technology, Inc. )

Brief Summary:

This is a study to compare the healing process of venous stasis ulcers when the Flexitouch® system is added to the standard treatment of venous ulcers. We hypothesize that adding the Flexitouch® system to standard venous ulcer treatment will result in

  1. greater complete healing
  2. greater percentage reduction in ulcer area
  3. reduced time to complete healing, as compared to the use of standard treatment alone
  4. a greater reduction in affected leg volume as compared to standard treatment alone.

Condition or disease Intervention/treatment Phase
Venous Ulcer Device: Standard Wound Care Device: Flexitouch System with Standard Wound Care Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Randomized Trial of Flexitouch as an Adjunctive Treatment for Venous Ulcers
Study Start Date : September 2007
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Standard Wound Care
Device: Standard Wound Care
Standard wound care treatment will include gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of the importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
Other Name: Farrow Wrap

Active Comparator: 2
Flexitouch system with Standard Wound Care
Device: Flexitouch System with Standard Wound Care
In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis. They will be instructed to remove the FarrowWrap during the time they are using Flexitouch. The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
Other Name: Flexitouch system

Primary Outcome Measures :
  1. Wound Healing [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Reduction in Leg Volume [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient must be at least 18 years old
  2. The ulcer maximum length x its maximum width must be greater or equal to 0 cm2
  3. The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone.
  4. The ulcer must have been present for more than 1 month.
  5. The ulcer must be located below the knee.
  6. The ulcer bed must have some viable tissues with some granulation tissue.

Exclusion Criteria:

  1. Exposed bone, tendon, or fascia
  2. Severe rheumatoid arthritis
  3. History of radiotherapy to the ulcer site
  4. Uncontrolled congestive heart failure
  5. Receiving corticosteroids or immune suppressive therapy
  6. History of collagen vascular disease
  7. Known malnutrition (albumin<3.0 g/dL). If malnutrition is suspected, the albumin level should be checked to determine if the patient meets the albumin criterion.
  8. The ulcer is clinically infected. However, patients may be entered into the study after successful treatment of infection.
  9. Known uncontrolled diabetes (HgbA1c > 8%). If uncontrolled diabetes is suspected, the Hgb A1c should be checked to determine patient eligibility.
  10. Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer bed(s).
  11. Known arterial insufficiency (Ankle-brachial index < 0.7, or TcPO2 < 35 mm Hg, or Toe-brachial index < 0.4). If peripheral vascular disease is suspected, vascular lab testing should be checked to determine patient eligibility.
  12. Active sickle cell disease
  13. Unable to comply with the procedures described in the protocol
  14. Enrolled in a clinical evaluation for another investigational wound-care device or drug
  15. Patients diagnosed with deep venous thrombosis or phlebitis in the affected limb in the last 6 months
  16. Pregnancy, suspected or confirmed
  17. Chronic renal disease, if deemed by the principal investigator to be severe enough to interfere with wound healing
  18. Known active or recurrent cancer, or currently receiving chemotherapy or radiation therapy
  19. History or pulmonary embolism
  20. Poorly controlled asthma
  21. Pulmonary Edema

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00847002

United States, Minnesota
VA Medical Center
Minneapolis, Minnesota, United States, 55417
United States, Texas
Wound Healing and Hyperbaric Center
College Station, Texas, United States, 77845
Sponsors and Collaborators
Tactile Systems Technology, Inc.
Principal Investigator: Wade Farrow, MD Wound Healing and Hyperbaric Center
Study Director: Sunday Hoy, JD Tactile Systems Techonology Inc.

Responsible Party: Tactile Systems Technology, Inc. Identifier: NCT00847002     History of Changes
Other Study ID Numbers: FWFT07312007
First Posted: February 19, 2009    Key Record Dates
Results First Posted: July 25, 2012
Last Update Posted: October 21, 2016
Last Verified: September 2016

Keywords provided by Tactile Medical ( Tactile Systems Technology, Inc. ):
Flexitouch system
venous stasis ulcer

Additional relevant MeSH terms:
Varicose Ulcer
Pathologic Processes
Varicose Veins
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases